"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
- Patient Information:
Details with Side Effects
Clinical experience with ADAGEN® (pegademase bovine) Injection has been limited. The following adverse reactions were reported during clinical trials: headache in one patient and pain at the injection site in two patients.
The following adverse reactions have been identified during post-approval use of ADAGEN® (pegademase bovine) Injection. Because these reactions are reported voluntarily from a very small population, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hematologic events: hemolytic anemia, auto-immune hemolytic anemia, thrombocythemia
To report SUSPECTED ADVERSE REACTIONS, contact Sigma-Tau Pharmaceuticals, Inc. at 1-888-393-4584 or by email at email@example.com or contact the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.
Read the Adagen (pegademase bovine) Side Effects Center for a complete guide to possible side effects
There are no known drug interactions with ADAGEN® (pegademase bovine) Injection. However, Vidarabine is a substrate for ADA and 2´-deoxycoformycin is a potent inhibitor of ADA. Thus, the activities of these drugs and ADAGEN® (pegademase bovine) Injection could be substantially altered if they are used in combination with one another.
Last reviewed on RxList: 10/17/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Adagen Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.